Shandong Xinhua Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Shandong Xinhua Pharmaceutical has a total shareholder equity of CN¥5.1B and total debt of CN¥1.7B, which brings its debt-to-equity ratio to 32.5%. Its total assets and total liabilities are CN¥8.8B and CN¥3.7B respectively. Shandong Xinhua Pharmaceutical's EBIT is CN¥476.7M making its interest coverage ratio 26. It has cash and short-term investments of CN¥1.2B.
Key information
32.5%
Debt to equity ratio
CN¥1.66b
Debt
| Interest coverage ratio | 26x |
| Cash | CN¥1.16b |
| Equity | CN¥5.10b |
| Total liabilities | CN¥3.73b |
| Total assets | CN¥8.82b |
Recent financial health updates
Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26
Recent updates
Shandong Xinhua Pharmaceutical (HKG:719) Is Paying Out A Larger Dividend Than Last Year
Jun 28Insufficient Growth At Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Hampers Share Price
Jan 23Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 05Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years
Jan 18Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?
Dec 29Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?
Dec 14Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26Financial Position Analysis
Short Term Liabilities: 719's short term assets (CN¥3.6B) exceed its short term liabilities (CN¥2.7B).
Long Term Liabilities: 719's short term assets (CN¥3.6B) exceed its long term liabilities (CN¥1.0B).
Debt to Equity History and Analysis
Debt Level: 719's net debt to equity ratio (9.8%) is considered satisfactory.
Reducing Debt: 719's debt to equity ratio has reduced from 47.7% to 32.5% over the past 5 years.
Debt Coverage: 719's debt is well covered by operating cash flow (26.8%).
Interest Coverage: 719's interest payments on its debt are well covered by EBIT (26x coverage).